AbbVie Inc. $ABBV Stock Holdings Lifted by Stenger Family Office LLC

Posted by Francis Steltz on Jul 9th, 2026

Stenger Family Office LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 16.0% in the first quarter, Holdings Channel.com reports. The fund owned 31,491 shares of the company’s stock after buying an additional 4,351 shares during the quarter. AbbVie comprises about 1.2% of Stenger Family Office LLC’s holdings, making the stock its 21st biggest position. Stenger Family Office LLC’s holdings in AbbVie were worth $6,849,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ABBV. Chelsea Counsel Co. purchased a new stake in shares of AbbVie during the third quarter valued at $26,000. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie in the 4th quarter valued at $28,000. Imprint Wealth LLC increased its stake in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares in the last quarter. Westend Capital Management LLC purchased a new position in AbbVie in the 4th quarter worth about $29,000. Finally, IFC & Insurance Marketing Inc. acquired a new stake in AbbVie during the 4th quarter worth about $31,000. 70.23% of the stock is owned by institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: The European Commission approved AbbVie’s Tepkinly in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, expanding the drug’s commercial opportunity in Europe and reinforcing AbbVie’s oncology growth pipeline. EC approves AbbVie’s Tepkinly combination for follicular lymphoma
Positive Sentiment: AbbVie completed a first-in-human study for ABBV-277, a clinical-stage program that could provide additional safety and efficacy data for investors watching the company’s next wave of pipeline assets. AbbVie’s ABBV‑277 Trial Completion: What Early Safety Data Could Mean for Investors
Neutral Sentiment: AbbVie’s upcoming second-quarter earnings report is expected to show double-digit EPS growth, but investors are focused on whether results can offset recent concerns around forward guidance and margin trends. AbbVie Earnings Preview: What to Expect
Negative Sentiment: AbbVie lowered its FY 2026 EPS guidance to $13.91-$14.11, below the consensus estimate of $14.25, and also guided Q2 EPS to $3.57-$3.61 versus expectations of $3.77, which is likely weighing on the shares today.

AbbVie Trading Down 0.7%

Shares of NYSE ABBV opened at $252.98 on Thursday. AbbVie Inc. has a one year low of $184.63 and a one year high of $261.64. The business has a 50-day moving average price of $223.50 and a two-hundred day moving average price of $220.90. The firm has a market capitalization of $446.96 billion, a PE ratio of 124.62, a PEG ratio of 0.84 and a beta of 0.30.

AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.46 EPS. Research analysts anticipate that AbbVie Inc. will post 14.19 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 340.89%.

Analyst Ratings Changes

A number of analysts have commented on ABBV shares. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Morgan Stanley lifted their target price on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. HSBC restated a “buy” rating and set a $300.00 price target on shares of AbbVie in a report on Monday. Canaccord Genuity Group raised their price objective on shares of AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. Finally, Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $256.67.

View Our Latest Stock Report on AbbVie

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.